MX2013008163A - Formas solidas de inhibidor de girasa (r)-1-etil-3-[5-[2-(1-hidrox i-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzim idazol-2-il]urea. - Google Patents

Formas solidas de inhibidor de girasa (r)-1-etil-3-[5-[2-(1-hidrox i-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzim idazol-2-il]urea.

Info

Publication number
MX2013008163A
MX2013008163A MX2013008163A MX2013008163A MX2013008163A MX 2013008163 A MX2013008163 A MX 2013008163A MX 2013008163 A MX2013008163 A MX 2013008163A MX 2013008163 A MX2013008163 A MX 2013008163A MX 2013008163 A MX2013008163 A MX 2013008163A
Authority
MX
Mexico
Prior art keywords
ethyl
solid forms
pyrimidin
tetrahydrofuran
urea
Prior art date
Application number
MX2013008163A
Other languages
English (en)
Other versions
MX351555B (es
Inventor
Yusheng Liao
Mariusz Krawiec
Brian Luisi
Dean Shannon
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45615044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013008163(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MX2013008163A publication Critical patent/MX2013008163A/es
Publication of MX351555B publication Critical patent/MX351555B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La solicitud actual se dirige a formas sólidas de los compuestos de la fórmula (I) (Ver Formula) y sales farmacéuticamente aceptables de los mismos, que inhiben la girasa bacteriana y/o Topo IV y composiciones farmacéuticas que comprenden dichos compuestos y sales. Estos compuestos y sales son útiles en el tratamiento de infección bacteriana.
MX2013008163A 2011-01-14 2012-01-13 Formas solidas de inhibidor de girasa (r)-1-etil-3-[5-[2-(1-hidrox i-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzim idazol-2-il]urea. MX351555B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161433161P 2011-01-14 2011-01-14
PCT/US2012/021275 WO2012097270A1 (en) 2011-01-14 2012-01-13 Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl}-1h-benzimidazol-2-yl]urea

Publications (2)

Publication Number Publication Date
MX2013008163A true MX2013008163A (es) 2013-08-27
MX351555B MX351555B (es) 2017-10-19

Family

ID=45615044

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008163A MX351555B (es) 2011-01-14 2012-01-13 Formas solidas de inhibidor de girasa (r)-1-etil-3-[5-[2-(1-hidrox i-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzim idazol-2-il]urea.

Country Status (17)

Country Link
US (2) US8481552B2 (es)
EP (1) EP2663558A1 (es)
JP (1) JP2014507413A (es)
KR (1) KR101897950B1 (es)
CN (1) CN103384666A (es)
AR (1) AR084862A1 (es)
AU (1) AU2012205416B2 (es)
BR (1) BR112013017977A2 (es)
CA (1) CA2824401A1 (es)
CL (1) CL2013002026A1 (es)
IL (1) IL227407B (es)
MX (1) MX351555B (es)
RU (1) RU2013137753A (es)
SG (1) SG191924A1 (es)
TW (1) TW201309676A (es)
WO (1) WO2012097270A1 (es)
ZA (1) ZA201305230B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2545516T3 (es) * 2011-01-14 2015-09-11 Vertex Pharmaceuticals Incorporated Inhibidores de la pirimidina girasa y la topoisomerasa IV
WO2012097274A1 (en) * 2011-01-14 2012-07-19 Vertex Pharmaceuticals Incorporation Process of making gyrase and topoisomerase iv inhibitors
KR101900249B1 (ko) * 2011-01-14 2018-11-02 스페로 트리넴, 인코포레이티드 자이라제 억제제 （ｒ）­１­에틸­３­［６­플루오로­５­［２­（１­하이드록시­１­메틸­에틸）피리미딘­５­일］­７­（테트라하이드로푸란­２­일）­１ｈ­벤즈이미다졸­２­일］우레아의 고체 형태
AU2012205416B2 (en) 2011-01-14 2017-02-02 Spero Therapeutics, Inc. Solid forms of gyrase inhibitor (R)-1-ethyl-3-(5-(2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl}-1H-benzimidazol-2-yl)urea
JP5977344B2 (ja) * 2011-06-20 2016-08-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ジャイレースおよびトポイソメラーゼ阻害剤のリン酸エステル
WO2014014845A1 (en) * 2012-07-18 2014-01-23 Vertex Pharmaceuticals Incorporated Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases
AR093226A1 (es) * 2012-07-18 2015-05-27 Vertex Pharma Formas solidas de dihidrogeno fosfato de (r)-2-(5-(2-(3-etilureido)-6-fluoro-7-(tetrahidrofuran-2-il)-1h-benzo[d]imidazol-5-il)pirimidin-2-il)propan-2-ilo y sus sales
JP2017504662A (ja) 2014-02-03 2017-02-09 スペロ ジャイレース インク ポリミキシンを含む抗菌剤の組合せ

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2015676A1 (de) 1970-04-02 1971-10-21 Farbenfabriken Bayer Ag, 5090 Leverkusen Neue Imine der 2-Formyl-chinoxalindi-N-oxidcarbon-säure-(3) und deren Salze, Verfahren zu ihrer Herstellung und ihre Verwendung als antimikrobielle Mittel
US4174400A (en) 1978-09-13 1979-11-13 Merck & Co., Inc. Anthelmintic benzimidazoles
US4512998A (en) 1980-10-20 1985-04-23 Schering Corporation Anthelmintic benzimidazole carbamates
CA2028530A1 (en) 1989-11-21 1991-05-22 Christian Hubschwerlen Substituted pyrimidobenzimidazole derivatives
DE19514313A1 (de) 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
HRP960159A2 (en) 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
US5643935A (en) 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
TW538046B (en) 1998-01-08 2003-06-21 Hoechst Marion Roussel Inc Aromatic amides having antiobiotic activities and the preparation processes, intermediates and pharmaceutical composition thereof
AUPP873799A0 (en) 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
GB9911594D0 (en) 1999-05-19 1999-07-21 Smithkline Beecham Plc Novel compounds
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
CA2433197C (en) * 2000-12-15 2009-11-24 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
RU2333208C2 (ru) 2002-06-13 2008-09-10 Вертекс Фармасьютикалз Инкорпорейтед Производные 2-уреидо-6-гетероарил-3н-бензимидазол-6-карбоновой кислоты и родственные соединения в качестве ингибиторов гиразы и/или топоизомеразы iv для лечения бактериальных инфекций
US7618974B2 (en) 2003-01-31 2009-11-17 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US8404852B2 (en) 2003-01-31 2013-03-26 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US8193352B2 (en) 2003-01-31 2012-06-05 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
US7569591B2 (en) 2003-01-31 2009-08-04 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
US7582641B2 (en) 2003-01-31 2009-09-01 Vertex Pharmaceuticals Incorporated Gyrase inhibitors and uses thereof
CN101321744A (zh) 2005-11-07 2008-12-10 沃泰克斯药物股份有限公司 作为回旋酶抑制剂的苯并咪唑衍生物
GB0724349D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Antibacterial agents
GB0612428D0 (en) 2006-06-22 2006-08-02 Prolysis Ltd Antibacterial agents
US8481544B2 (en) 2006-06-22 2013-07-09 Biota Europe Limited Antibacterial compositions
UA96964C2 (ru) 2006-12-04 2011-12-26 Астразенека Аб Соединения полициклической мочевины с антибактериальными свойствами
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
US20110166088A1 (en) 2008-06-25 2011-07-07 Ranbaxy Laboratories Limited Benzothiazoles and aza-analogues thereof use as antibacterial agents
WO2011032050A2 (en) 2009-09-11 2011-03-17 Trius Therapeutics, Inc. Gyrase inhibitors
WO2011047323A2 (en) 2009-10-16 2011-04-21 Rib-X Pharmaceuticals, Inc. Antimicrobial compounds and methods of making and using the same
EP2625178A4 (en) 2010-10-08 2014-04-30 Biota Europe Ltd BACTERIA TOPOISOMERASE II FOR INHIBITING 2-ETHYL CARBAMOYLAMINE-1,3-BENZOTHIAZOL-5-YLENE
WO2012097274A1 (en) * 2011-01-14 2012-07-19 Vertex Pharmaceuticals Incorporation Process of making gyrase and topoisomerase iv inhibitors
ES2545516T3 (es) * 2011-01-14 2015-09-11 Vertex Pharmaceuticals Incorporated Inhibidores de la pirimidina girasa y la topoisomerasa IV
AU2012205416B2 (en) 2011-01-14 2017-02-02 Spero Therapeutics, Inc. Solid forms of gyrase inhibitor (R)-1-ethyl-3-(5-(2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl}-1H-benzimidazol-2-yl)urea
KR101900249B1 (ko) * 2011-01-14 2018-11-02 스페로 트리넴, 인코포레이티드 자이라제 억제제 （ｒ）­１­에틸­３­［６­플루오로­５­［２­（１­하이드록시­１­메틸­에틸）피리미딘­５­일］­７­（테트라하이드로푸란­２­일）­１ｈ­벤즈이미다졸­２­일］우레아의 고체 형태
JP5977344B2 (ja) * 2011-06-20 2016-08-24 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ジャイレースおよびトポイソメラーゼ阻害剤のリン酸エステル
WO2014014845A1 (en) * 2012-07-18 2014-01-23 Vertex Pharmaceuticals Incorporated Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases
AR093226A1 (es) * 2012-07-18 2015-05-27 Vertex Pharma Formas solidas de dihidrogeno fosfato de (r)-2-(5-(2-(3-etilureido)-6-fluoro-7-(tetrahidrofuran-2-il)-1h-benzo[d]imidazol-5-il)pirimidin-2-il)propan-2-ilo y sus sales

Also Published As

Publication number Publication date
CN103384666A (zh) 2013-11-06
EP2663558A1 (en) 2013-11-20
IL227407B (en) 2018-01-31
AU2012205416A1 (en) 2013-08-01
JP2014507413A (ja) 2014-03-27
US20120184741A1 (en) 2012-07-19
RU2013137753A (ru) 2015-02-20
CL2013002026A1 (es) 2013-12-27
AU2012205416B2 (en) 2017-02-02
SG191924A1 (en) 2013-08-30
KR20140037029A (ko) 2014-03-26
WO2012097270A1 (en) 2012-07-19
BR112013017977A2 (pt) 2019-09-24
AR084862A1 (es) 2013-06-26
MX351555B (es) 2017-10-19
TW201309676A (zh) 2013-03-01
US8481552B2 (en) 2013-07-09
ZA201305230B (en) 2014-11-26
CA2824401A1 (en) 2012-07-19
US20130317222A1 (en) 2013-11-28
NZ612912A (en) 2015-10-30
KR101897950B1 (ko) 2018-09-12
IL227407A0 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
MX351555B (es) Formas solidas de inhibidor de girasa (r)-1-etil-3-[5-[2-(1-hidrox i-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzim idazol-2-il]urea.
MX341342B (es) Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2 -(1-hidroxi-1-metil-etil) pirimidin-5-il]-7-(tetrahidrofuran-2-il) -1h-benzimidazol-2-il]urea.
CA2875877C (en) Syk inhibitors
WO2008145688A3 (en) Pyrrolopyridine compounds, process for their preparation, and their use as medicaments
MX336381B (es) Boronatos como inhibidores de arginasa.
MX338707B (es) Compuestos heterociclicos activadores de proteina cinasa activada por 5'-amp (ampk) y metodos para emplearlos.
MD4625B1 (ro) Derivaţi de 5-fenoxi-3H-pirimidin-4-onă şi utilizarea acestora ca inhibitori ai transcriptazei inverse a HIV
MD4556C1 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
MD20140047A2 (ro) Inhibitori ai protein kinazei
MY171577A (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
WO2012083122A8 (en) Inhibitors of influenza viruses replication
MX339149B (es) Inhibidores de replicacion del virus de influenza.
MX2013006846A (es) Inhibidores de la replicacion de los virus de la influenza.
MX348422B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
MY184858A (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
TN2012000455A1 (en) Non-nucleoside reverse transcriptase inhibitors
MX2011011083A (es) Compuestos heterociclicos como inhibidores de mek.
WO2013106761A3 (en) Antimicrobial agents
NZ596628A (en) Ketolide compounds having antimicrobial activity
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
MX341577B (es) Derivados biciclicos de pirimidin-urea o carbamato sustituidos con morfolino como inhibidores del blanco de rapamicina de mamifero.
EP2865668A3 (en) Inhibitors and methods of inhibiting bacterial and viral pathogens
AU2012225365A8 (en) Peptide deformylase inhibitors

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: SPERO TRINEM, INC.

FG Grant or registration